Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update

Advances in Medical Sciences

Volumn 61, Issue 1, 2016, Pages 63-71

  Njire, Moses ^a   Tan, Yaoju ^b   Mugweru, Julius ^a   Wang, Changwei ^a   Guo, Jintao ^a   Yew, WingWai ^c   Tan, Shouyong ^b   Zhang, Tianyu ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b GUANGZHOU CHEST HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Drug resistance; MDR; Pyrazinamide; Tuberculosis; XDR

Indexed keywords

PYRAZINAMIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; HUMAN; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; TUBERCULOSIS;

ANIMALS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS;

EID: 84960154503     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2015.09.007     Document Type: Review

References (97)

1. P. Smith, and A. Moss Epidemiology of tuberculosis Tuberculosis: pathogenesis, protection and control 1994 47
2. World Health Organization The stop TB strategy 2006 World Health Organization Geneva, Switzerland
3. World Health Organization Global tuberculosis report 2014 2014 World Health Organization
4. S. Loewenberg India reports cases of totally drug-resistant tuberculosis Lancet 379 9812 2012 205 10.1016/S0140-6736(12)60085-3
5. M. Klopper, R.M. Warren, C. Hayes, N.C.G. van Pittius, E.M. Streicher, B. Müller, and et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa Emerg Infec Dis 19 3 2013 449 10.3201//EID1903.120246
6. Z. Udwadia, and D. Vendoti Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining J Epidemiol Community Health 67 6 2013 471 472 10.1136/jech-2012-201640
7. G. Migliori, G. De Iaco, G. Besozzi, R. Centis, and D. Cirillo First tuberculosis cases in Italy resistant to all tested drugs Euro Surveill 12 5 2007 E070517
8. A.A. Velayati, M.R. Masjedi, P. Farnia, P. Tabarsi, J. Ghanavi, A.H. ZiaZarifi, and et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran Chest J 136 2 2009 420 425
9. L. Heifets, and P. Linddholm-Levy Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations Am Rev Respir Dis 145 5 1992 1223 1225 10.1164/ajrccm/145.5.1223
10. D. Mitchison The action of antituberculosis drugs in short-course chemotherapy Tubercle 66 3 1985 219 225 10.1016/0041-3879(85)900406
11. G.A. Deye, M. Gettayacamin, P. Hansukjariya, R. Im-erbsin, J. Sattabongkot, Y. Rothstein, and et al. Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances Am J Trop Med Hyg 86 6 2012 931 935 10.4269/ajtmh.2012.11-0552
12. M.M. Wade, and Y. Zhang Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro J Antimicrob Chemother 58 5 2006 936 941 10.1093/jac/dkl358
13. K. Lewis Persister cells Annu Rev Microbiol 64 2010 357 372 10.1146/annurev.micro.112408.134306
14. A.R. Coates, and Y. Hu Targeting non-multiplying organisms as a way to develop novel antimicrobials Trends Pharmacol Sci 29 3 2008 143 150 10.1016/j.tips.2007.12.001
15. C. Nathan Fresh approaches to anti-infective therapies Sci Transl Med 4 140 2012 140sr2 10.1126/scitranslmed.3003081
16. Y. Zhang, and D. Mitchison The curious characteristics of pyrazinamide: a review Int J Tuberc Lung Dis 7 1 2003 6 21
17. K. Konno, F. Feldmann, and W. McDermott Pyrazinamide susceptibility and amidase activity of tubercle bacilli Am Rev Respir Dis 95 1967 461 469
18. A. Scorpio, and Y. Zhang Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus Nat Med 2 6 1996 662 667 10.1038/nm0696-662
19. S. Budavari, M.J. O'Neil, A. Smith, and P.E. Heckelman The Merck index 1989 Merck & Co. Inc. Rahway, NJ 1481
20. K. Hirano, M. Takahashi, Y. Kazumi, Y. Fukasawa, and C. Abe Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis Tuber Lung Dis 78 2 1998 117 122 10.1016/S0962-8479(98)80004-X
21. Y. Zhang, W. Shi, W. Zhang, and D. Mitchison Mechanisms of pyrazinamide action and resistance Microbiol Spectr 2 4 2013 1 10.1128/microbiolspec.MGM2-0023-2013
22. D.C. Alexander, J.H. Ma, J.L. Guthrie, J. Blair, P. Chedore, and F.B. Jamieson Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA J Clin Microbiol 50 11 2012 3726 3728 10.1128/JCM. 00620-12
23. N. Lemaitre, I. Callebaut, F. Frenois, V. Jarlier, and W. Sougakoff Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis Biochem J 353 2001 453 458
24. P. Sheen, P. Ferrer, R.H. Gilman, J. López-Llano, P. Fuentes, E. Valencia, and et al. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis Tuberculosis 89 2 2009 109 113 10.1016/j.tube.2009.01.004
25. X. Du, W. Wang, R. Kim, H. Yakota, H. Nguyen, and S.-H. Kim Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii Biochem J 40 47 2001 14166 14172 10.1021/bi0115479
26. S. Petrella, N. Gelus-Ziental, A. Maudry, C. Laurans, R. Boudjelloul, and W. Sougakoff Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide PLoS ONE 6 1 2011 e15785 10.1371/journal.pone.0015785
27. O. Zimhony, C. Vilchèze, M. Arai, J.T. Welch, and W.R. Jacobs Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli Antimicrob Agents Chemother 51 2 2007 752 754 10.1128/AAC. 01369-06
28. Y. Zhang, M.M. Wade, A. Scorpio, H. Zhang, and Z. Sun Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid J Antimicrob Chemother 52 5 2003 790 795 10.1093/jac/dkg446
29. M. Salfinger, A.J. Crowle, and L.B. Reller Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system J Infect Dis 162 1 1990 201 207 10.1093/infdis/162.1.201
30. S. Sturgill-Koszycki, P.H. Schlesinger, P. Chakraborty, P.L. Haddix, H.L. Collins, A.K. Fok, and et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase Science 263 5147 1994 678 681 10.1126/science.8303277
31. L. Heifets, M. Higgins, and B. Simon Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages Int J Tuberc Lung Dis 4 6 2000 491 495 [Unresolved issues]
32. O.H. Vandal, L.M. Pierini, D. Schnappinger, C.F. Nathan, and S. Ehrt A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis Nat Med 14 8 2008 849 854 10.1038/nm.1795
33. T. Zhang, S.-Y. Li, and E.L. Nuermberger Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy PLoS ONE 7 1 2012 e29774 10.1371/journal.pone.0029774
34. Y. Zhang, A. Scorpio, H. Nikaido, and Z. Sun Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide J Bacteriol 181 7 1999 2044 2049
35. H.I. Boshoff, V. Mizrahi, and C.E. Barry Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I J Bacteriol 184 8 2002 2167 2172 10.1128/JB.184.8.2167-2172.2002
36. H. Kim, K. Shibayama, E. Rimbara, and S. Mori Biochemical characterization of quinolinic acid phosphoribosyltransferase from Mycobacterium tuberculosis H37Rv and inhibition of its activity by pyrazinamide PLOS ONE 9 6 2014 e100062 10.1371/journal.pone.0100062
37. L.E. Via, R. Savic, D.M. Weiner, M.D. Zimmerman, B. Prideaux, S.M. Irwin, and et al. Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance, and therapeutic alternatives ACS Infect Dis 1 5 2015 203 214 10.1021/id500028m
38. N. Kamal, P. Mukerji, K. Kishore, S. Kumar, and B. Khanna Serum levels of pyrazinamide and pyrazinoic acid following long term administration of pyrazinamide orally Ind J Tub 23 1976 19 25
39. C. Lacroix, T.P. Hoang, J. Nouveau, C. Guyonnaud, G. Laine, H. Duwoos, and et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects Eur J Clin Pharmacol 36 4 1989 395 400
40. K. Fuursted Comparison of growth and susceptibility testing of pyrazinamide in different Bactec media using strains of the Mycobacterium tuberculosis complex APMIS 101 1-6 1993 154 159 10.1111/j.1699-0463.1993.tb00095.x
41. R. Tummon Growth inhibition of Mycobacterium tuberculosis by oleate in acidified medium Med Lab Technol 32 3 1975 229 232
42. W. McDermott, and R. Tompsett Activation of pyrazinamide and nicotinamide in acidic environments in vitro Am Rev Respir Dis 70 4 1954 748 754
43. L.B. Heifets, and J. Lindholm-Levy Is pyrazinamide bactericidal against Mycobacterium tuberculosis? 1-3 Am Rev Respir Dis 141 1990 250 252 10.1164/ajrccm/141.1.250
44. G. Ellard Absorption, metabolism and excretion of pyrazinamide in man Tubercle 50 2 1969 144 158 10.1016/0041-3879(69)90020-8
45. G. Louw, R. Warren, P. Donald, M. Murray, M. Bosman, P. Van Helden, and et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients Int J Tuberc Lung Dis 10 7 2006 802 807
46. H.J. Marttila, M. Marjamäki, E. Vyshnevskaya, B.I. Vyshnevskiy, T.F. Otten, A.V. Vasilyef, and et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Northwestern Russia Antimicrob Agents Chemother 43 7 1999 1764 1766
47. J. Werngren, E. Sturegård, P. Juréen, K. Ängeby, S. Hoffner, and T. Schön Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing Antimicrob Agents Chemother 56 3 2012 1253 1257 10.1128/AAC. 05894-11
48. L.G. Wayne Simple pyrazinamidase and urease tests for routine identification of mycobacteria Am Rev Respir Dis 109 1 1974 147 151
49. X. Gonzalo, F. Drobniewski, S. Hoffner, and J. Werngren Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis J Antimicrob Chemother 2014 dku230 10.1093/jac/dku230
50. N. Carlone, G. Acocella, A. Cuffini, and M. Forno-Pizzoglio Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination Am Rev Respir Dis 132 6 1985 1274 1277
51. A. Crowle, J. Sbarbaro, and M. May Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages Am Rev Respir Dis 134 5 1986 1052 1055
52. A.J. Crowle, R. Dahl, E. Ross, and M.H. May Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic Infect Immun 59 5 1991 1823 1831
53. N. Rastogi, M. Potar, and H. David Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis Antimicrob Agents Chemother 32 2 1988 287
54. P. Juréen, J. Werngren, J.-C. Toro, and S. Hoffner Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis Antimicrob Agents Chemother 52 5 2008 1852 1854 10.1128/AAC.00110-08
55. C.U.C.I. Köser, S. Feuerriegel, S. Niemann, S. Gagneux, and S.J. Peacock Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay Tuberculosis 94 2014 451 453 10.1016/j.tube.2014.04.002
56. M. Zhou, X. Geng, J. Chen, X. Wang, D. Wang, J. Deng, and et al. Rapid colorimetric testing for pyrazinamide susceptibility of Mycobacterium tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method PLoS ONE 6 11 2011 e27654 10.1371/journal.pone.0027654
57. Y. Tan, Z. Hu, T. Zhang, X. Cai, H. Kuang, Y. Liu, and et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from Southern China J Clin Microbiol 52 1 2014 291 297 10.1128/JCM.01903-13
58. S. Sreevatsan, X. Pan, Y. Zhang, B.N. Kreiswirth, and J.M. Musser Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms Antimicrob Agents Chemother 41 3 1997 636 640
59. A. Scorpio, P. Lindholm-Levy, L. Heifets, R. Gilman, S. Siddiqi, M. Cynamon, and et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis Antimicrob Agents Chemother 41 3 1997 540 543
60. A.S. Kalokhe, M. Shafiq, J.C. Lee, S.M. Ray, Y.F. Wang, B. Metchock, and et al. Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing: a review of the literature Am J Med Sci 345 2 2013 143 10.1097/MAJ.0b013e31825d32c6
61. Y. Zhang, and W. Yew Mechanisms of drug resistance in Mycobacterium tuberculosis Int J Tuberc Lung Dis 13 11 2009 1320 1330 [State of the art series Drug-resistant tuberculosis. Edited by CY. Chiang. Number 1 in the series]
62. S.C. Ngo, O. Zimhony, W.J. Chung, H. Sayahi, W.R. Jacobs, and J.T. Welch Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs Antimicrob Agents Chemother 51 7 2007 2430 2435 10.1128/AAC.01458-06
63. C. Raynaud, M.-A. Lanéelle, R.H. Senaratne, P. Draper, G. Lanéelle, and M. Daffé Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity Microbiology 145 6 1999 1359 1367 10.1099/13500872-145-6-1359
64. T.-S. Huang, S.S.-J. Lee, H.-Z. Tu, W.-K. Huang, Y.-S. Chen, C.-K. Huang, and et al. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan Antimicrob Agents Chemother 47 11 2003 3672 3673 10.1128/AAC.47.11.3672-3673.2003
65. S. Bhuju, L. de Souza Fonseca, A.G. Marsico, G.B. de Oliveira Vieira, L.F. Sobral, M. Stehr, and et al. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene Infect Genet Evol 19 2013 1 6 10.1016/j.meegid.2013.06.008
66. K. Bishop, L. Blumberg, A. Trollip, A. Smith, L. Roux, D. York, and et al. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa Int J Tuberc Lung Dis 5 10 2001 952 957
67. C. Miyagi, N. Yamane, B. Yogesh, H. Ano, and T. Takashima Genetic and phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis complex isolates in Japan Diagn Microbiol Infect Dis 48 2 2004 111 116 10.1016/j.diagmicrobio.2003.09.013
68. V.d.F.S. Rodrigues, M.A. Telles, M.O. Ribeiro, P.I. Cafrune, M.L.R. Rossetti, and A. Zaha Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil Antimicrob Agents Chemother 49 1 2005 444 446 10.1128/AAC.49.1.444-446.2005
69. R.C. Chan, M. Hui, E.W. Chan, T. Au, M.L. Chin, C.K. Yip, and et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong J Antimicrob Chemother 59 5 2007 866 873 10.1093/jac/dkm054
70. S. Pandey, S. Newton, A. Upton, S. Roberts, and D. Drinković Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand Pathology 41 6 2009 582 584 10.1080/00313020903071587
71. J. Jonmalung, T. Prammananan, M. Leechawengwongs, and A. Chaiprasert Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand BMC Microbiol 10 1 2010 223 10.1186/1471-2180-10-223
72. M. Mphahlele, H. Syre, H. Valvatne, R. Stavrum, T. Mannsåker, T. Muthivhi, and et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates J Clin Microbiol 46 10 2008 3459 3464 10.1128/JCM.00973-08
73. L. Hou, D. Osei-Hyiaman, Z. Zhang, B. Wang, A. Yang, and K. Kano Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China Epidemiol Infect 124 02 2000 227 232
74. K.W. Lee, J.M. Lee, and K.S. Jung Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea J Korean Med Sci 16 5 2001 537
75. S.O. Simons, J. van Ingen, T. van der Laan, A. Mulder, P.R. Dekhuijzen, M.J. Boeree, and et al. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide J Clin Microbiol 50 2 2012 428 434 10.1128/JCM.05435-11
76. Y. Zhang, S. Permar, and Z. Sun Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide J Med Microbiol 51 1 2002 42 49
77. S. Klemens, C. Sharpe, and M. Cynamon Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility Antimicrob Agents Chemother 40 1 1996 14 16
78. A. Aono, K. Chikamatsu, H. Yamada, T. Kato, and S. Mitarai The association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis Antimicrob Agents Chemother 58 8 2014 4928 4930 10.1128/AAC.02394-14
79. J.-H. Yoon, J.-S. Nam, K.-J. Kim, and Y.-T. Ro Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Korea and analysis of the correlation between the mutations and pyrazinamidase activity World J Microbiol Biotechnol 2014 1 8
80. W. Shi, X. Zhang, X. Jiang, H. Yuan, J.S. Lee, C.E. Barry, and et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 333 6049 2011 1630 1632 10.1126/science.1208813
81. E.N. Ilina, E.A. Shitikov, L.N. Ikryannikova, D.G. Alekseev, D.E. Kamashev, M.V. Malakhova, and et al. Comparative genomic analysis of Mycobacterium tuberculosis drug resistant strains from Russia PLOS ONE 8 2 2013 e56577 10.1371/journal.pone.0056577
82. S.O. Simons, A. Mulder, J. van Ingen, M.J. Boeree, and D. van Soolingen Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance J Clin Microbiol 51 1 2013 382 10.1128/JCM.02739-12
83. A. Akhmetova, U. Kozhamkulov, V. Bismilda, L. Chingissova, T. Abildaev, M. Dymova, and et al. Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan Int J Tuberc Lung Dis 19 2 2015 179 184
84. S. Zhang, J. Chen, W. Shi, W. Liu, W. Zhang, and Y. Zhang Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis Emerg Microbes Infect 2 6 2013 e34 10.1038/emi.2013.38
85. W. Shi, J. Chen, J. Feng, P. Cui, S. Zhang, X. Weng, and et al. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis Emerg Microbes Infect 3 8 2014 e58 10.1038/emi.2014.61
86. N.A. Dillon, N.D. Peterson, B.C. Rosen, and A.D. Baughn Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide Antimicrob Agents Chemother 58 12 2014 7258 7263 10.1128/AAC.04028-14
87. V.K. Sambandamurthy, X. Wang, B. Chen, R.G. Russell, S. Derrick, F.M. Collins, and et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis Nat Med 8 10 2002 1171 1174 10.1038/nm765
88. K.-C. Chang, C.-C. Leung, W.-W. Yew, E.C.-C. Leung, W.-M. Leung, C.-M. Tam, and et al. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis Antimicrob Agents Chemother 2012 10.1128/AAC.01300-12 01300-12
89. East African/British Medical Research Council Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis: third report Lancet 304 7875 1974 237 240 10.1016/S0140-6736(74)91411-1
90. East African/British Medical Research Council Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary, tuberculosis. Second report Am Rev Respir Dis 114 3 1976 471 475
91. East African/British Medical Research Council Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report Tubercle 61 2 1980 59 69 10.1016/0041-3879(80)90012-4
92. Z. Ahmad, S. Tyagi, A. Minkowski, C.A. Peloquin, J.H. Grosset, and E.L. Nuermberger Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis Am J Respir Crit Care Med 188 1 2013 97 102 10.1164/rccm.201212-2328OC
93. R. Dawson, A.H. Diacon, D. Everitt, C. van Niekerk, P.R. Donald, D.A. Burger, and et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Lancet 385 9979 2015 1738 1747 10.1016/S0140-6736(14)62002-X
94. F. Brossier, N. Veziris, V. Jarlier, and W. Sougakoff Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid Int J Tuberc Lung Dis 13 2 2009 260 265
95. K. Ajbani, C. Nikam, M. Kazi, C. Gray, C. Boehme, K. Balan, and et al. Evaluation of genotype MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments PLoS ONE 7 1 2012 e49433 10.1371/journal.pone.0049433
96. P. Juréen, J. Werngren, and S.E. Hoffner Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis Tuberculosis 84 5 2004 311 316 10.1016/j.tube.2003.12.001
97. P. Miotto, A.M. Cabibbe, S. Feuerriegel, N. Casali, F. Drobniewski, Y. Rodionova, and et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study MBio 5 5 2014 e01819 e1914 10.1128/mBio.01819-14